Literature DB >> 27797315

Adaptive Randomization of Neratinib in Early Breast Cancer.

Marc Buyse1, Everardo D Saad1, Tomasz Burzykowski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27797315     DOI： 10.1056/NEJMc1609993

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.

Authors:  W Charles Huskins; Vance G Fowler; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

2.  The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.

Authors:  Alessio Crippa; Bram De Laere; Andrea Discacciati; Berit Larsson; Jason T Connor; Erin E Gabriel; Camilla Thellenberg; Elin Jänes; Gunilla Enblad; Anders Ullen; Marie Hjälm-Eriksson; Jan Oldenburg; Piet Ost; Johan Lindberg; Martin Eklund; Henrik Grönberg
Journal:  Trials       Date:  2020-06-26       Impact factor: 2.279

3.  The impact of selection bias in randomized multi-arm parallel group clinical trials.

Authors:  Diane Uschner; Ralf-Dieter Hilgers; Nicole Heussen
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.